HIV vaccine development in the nonhuman primate model of AIDS

Journal of Biomedical Science

Volumn 9, Issue 2, 2002, Pages 100-111

  Smith, Stephen M ^a  

^a ST MICHAEL S MEDICAL CENTER   (United States)

Author keywords

HIV; Macaque; Simian immunodeficiency virus; Vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; TRANSACTIVATOR PROTEIN; VIRUS VECTOR; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DISEASE MODEL; DNA VECTOR; HISTORY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; MEDICAL RESEARCH; NONHUMAN; POXVIRUS; PRIMATE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; VIRUS ACTIVATION; VIRUS ATTENUATION; ANIMAL; CELLULAR IMMUNITY; GENE VECTOR; HUMAN; IMMUNOLOGY; MONKEY DISEASE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIMATES; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ANIMALS; DISEASE MODELS, ANIMAL; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; PRIMATES; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIRAL PROTEINS;

EID: 0035991866     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1159/000048205     Document Type: Review

References (126)

1. Protection of macaques against simian immunodeficiency virus infection with inactivated vaccines: Comparison of adjuvants, doses and challenge viruses. The European Concerted Action on 'Macaque Models for AIDS Research'
2. HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV- 2 challenge in rhesus macaques
3. Vaccines
4. Reduced virus load in rhesus macaques immunized with recombinant gp 160 and challenged with simian immunodeficiency virus
5. DNA vaccination of macaques by a full genome HIV- plasmid which produces noninfections virus particles
6. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia
7. Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells
8. Control of a mucosal challenge and prevention of AIDS by a mul-tiprotein DNA/MVA vaccine
9. Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus
10. Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp 120
11. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques
12. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
13. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques
14. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region
15. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination
16. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
17. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques
18. Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): Dependence on route of challenge exposure
19. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp 120 but not gp160
20. Protection of chimpanzees from high-dose heterologous HIV- 1 challenge by DNA vaccination
21. Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp 120 boosting regimen and challenged vaginally with SIVmac251
22. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge
23. A vaccine for HIV type 1: The antibody perspective
24. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine
25. A candidate live inactivatable attenuated vaccine for AIDS
26. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region
27. DNA vaccination with the human immunodeficiency virus type 1 SF162Delta V2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques
28. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous simian/human immunodeficiency virus infection in pigtailed macaques
29. AIDS research. Debate begins over new vaccine trials
30. AIDS research. Merck reemerges with a bold AIDS vaccine effort
31. The immunology of human immunodeficiency virus infection
32. Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine
33. Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors
34. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene
35. High-titer immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infection
36. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles
37. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients
38. Epidemiology and prevention of acquired immunodeficiency syndrome and human immunodeficiency virus infection
39. Vaccine protection against simian immunodeficiency virus infection
40. Immunogenicity and protective efficacy of oligomer-ic human immunodeficiency virus type 1 gp140
41. Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection
42. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients
43. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation
44. Neutralizing antibodies administered before, but not after, virulent SHIV prevent infection in macaques
45. Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long-lasting protection in rhesus macaques
46. The AIDSVAX B/B phase III efficacy trial in North America and the Netherlands
47. Cellular uptake of the tat protein from human immunodeficiency virus
48. Replication-incompetent recombinant adenovirus vector expressing SIV gag elicits robust and effective cellular immune responses in rhesus macaques
49. SIVsmmPBj14: An atypical lentivirus
50. Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine
51. Passive immunization of rhesus macaques against SIV infection and disease
52. The history of simian AIDS
53. Expression of gamma interferon by simian immunodeficiency virus increases attenuation and reduces postchallenge virus load in vaccinated rhesus macaques
54. Immunization with whole inactivated vaccine protects from infection by SIV grown in human but not macaque cells
55. Protection of Macaca nemestrina from disease following pathogenic simian immunodeficiency virus (SIV) challenge: Utilization of SIV nucleocapsid mutant DNA vaccines with and without an SIV protein boost
56. HIV vaccines: Where we are and where we are going
57. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: Effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara
58. Simian immunodeficiency virus infection of monkeys as a model system for the study of AIDS pathogenesis, treatment, and prevention
59. Two chimps, too few
60. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp 160
61. Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines
62. Primate models of AIDS
63. Passively administered neutralizing serum that protected macaques against infection with parenterally inoculated pathogenic simian-human immunodeficiency virus failed to protect against mucosally inoculated virus
64. Protective immunity induced by live attenuated simian immunodeficiency virus
65. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: Inverse relationship of degree of protection with level of attenuation
66. Intrarectal challenge of macaques immunized with VEE replicon vectors
67. Enhanced safety and efficacy of live attenuated SIV vaccines by prevaccination with recombinant vaccines
68. Passive immunization of cynomolgus macaques with immune sera or a pool of neutralizing monoclonal antibodies failed to protect against challenge with SIVmac 251
69. Animal models for acquired immunodeficiency syndrome
70. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: Effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses
71. Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus
72. Specific and non-specific immunity and protection of macaques against SIV infection
73. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort
74. Alloimmunization as a strategy for vaccine design against HIV/AIDS
75. Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope
76. Limited protection from a pathogenic chimeric simian-human immunodeficiency virus challenge following immunization with attenuated simian immunodeficiency virus
77. Attenuated retrovirus vaccines AIDS
78. In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies
79. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
80. Protection against SIV infection in macaques by immunization with inactivated virus from the BK28 molecular clone, but not with BK28-derived recombinant env and gag proteins
81. A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection
82. Protection against lethal simian immunodeficiency virus SIVsmmPBj 14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine
83. Immunization against SIVmne in macaques using multigenic DNA vaccines
84. A formalin-inactivated whole SIV vaccine confers protection in macaques
85. Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques
86. Challenges and opportunities for development of an AIDS vaccine
87. Simian immunodeficiency virus-specific cytotoxic T lymphocytes and protection against challenge in rhesus macaques immunized with a live attenuated simian immunodeficiency virus vaccine
88. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV
89. Applications of pox virus vectors to vaccination: An update
90. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/ human immunodeficiency virus at serum levels giving complete neutralization in vitro
91. Failure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV
92. Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys
93. A role for carbohydrates in immune evasion in AIDS
94. Attenuated vesicular stomatitis viruses as vaccine vectors
95. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge
96. Working toward an AIDS Vaccine
97. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants
98. Production, characterization, and oligomeric stabilization of recombinant disulfide linked (SOS) HIV-1 envelope glycoproteins
99. Update on antiviral DNA vaccine research (1998-2000)
100. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge
101. Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: Influence of pre-existing anti-vector immunity
102. Alloimmunization for immune-based therapy and vaccine design against HIV/AIDS
103. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys
104. Humoral and cellular immune responses induced by HIV tat protein fail to confer protection against SHIV89.6P infection
105. Retrospective analysis of viral load and SIV antibody responses in rhesus macaques infected with pathogenic SIV: Predictive value for disease progression
106. Strategies and applications of alphavirus vectors in gene therapy
107. Constitutively dead, conditionally live HIV-1 genomes. Ex vivo implications for a live virus vaccine
108. Conditional reduction of human immunodeficiency virus type 1 replication by a gain-of-herpes simplex virus 1 thymidine kinase function
109. Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virus
110. Vaccination against SIV withtatandrev
111. Anti-cell antibody in macaques
112. Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: Effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 chimeric virus
113. Protection of macaques against a SHIV with a homologous HIV-1 Env and a pathogenic SHIV-89.6P with a heterologous Env by vaccination with multiple gene-deleted SHIVs
114. Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection
115. Strict control of human immunodeficiency virus type 1 replication by a genetic switch: Tet for Tat
116. Immunization with tat and rev induces partial protection from mucosal SHIV infection in rhesus macaques
117. Protection provided by hepatitis B vaccine in a Yupik Eskimo population - Results of a 10-year study
118. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population
119. Protection provided by hepatitis B vaccine in a Yupik Eski-mo population. Seven-year results
120. Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virions
121. Human immunodeficiency virus type 1 Tat upregulates interleukin-2 secretion in activated T cells
122. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge
123. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus
124. Resistance of neonatal monkeys to live attenuated vaccine strains of simian immunodeficiency virus
125. Selective CXCR4 antagonism by Tat: Implications for in vivo expansion of coreceptor use by HIV-1